Search results
Added:
1 year ago
CRT 25 - Insights on the progression risk in patients with mild to moderate aortic stenosis (AS) show that there was no significant difference in progression rates between mild and moderate AS. However, moderate AS patients had significantly higher mortality rates than mild AS patients at one- and two-year follow ups. The study also suggests that elevated phosphate levels and elevated…
View more
Added:
11 months ago
Findings from a retrospective trial show GLP-1 medications for moderate peripheral artery disease (PAD) significantly decreased the risk of amputations.Dr Catherine Go (Charleston Area Medical Center, Charleston, WV, US) joins us to discuss outcomes from the largest retrospective trial evaluating the impact of GLP-1 medications for patients with moderate PAD. The study used the TriNetX database…
View more
Added:
1 year ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial…
View more
Added:
2 months ago
Source:
Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension…
View more
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)…
View more
Added:
1 month ago
American College of Cardiology Congress 2026 – Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us to discuss primary results from the MOMENTUM study (NCT06829537; Corcept Therapeutics) investigating the prevalence and clinical impact of endogenous hypercortisolism in patients with resistant hypertension.This prospective, cross-sectional observational study enrolled 1,143…
View more
Added:
1 year ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only…
View more
Left Atrial Myxoma
Added:
1 year ago
Case Report
Pathophysiology, Mechanism, Diagnosis and Management of PAH
Added:
3 months ago
Review Article
Added:
6 months ago
TCT 2025 - The PREVUE-VALVE study finds an 8.2% prevalence of moderate or greater valvular heart disease amongst Americans age 65-85, increasing to 18.4% when participants with mild to moderate VHD were included.Dr David J. Cohen (Cardiovascular Research Foundation & St Francis Hospital, US) joins us to discuss findings from the PREVUE-VALVE study, examining age and sex-specific prevalence of…
View more